A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults

Conditions

Prevention of influenza infection in older adults

Brief summary

Hospitalization due to influenza or pneumonia [composite endpoint]

Detailed description

1) Hospitalization for any cardio-respiratory disease [composite endpoint], 2) All-cause hospitalization, 3) All-cause mortality, 4) Hospitalization for influenza, 5) Hospitalization for pneumonia

Nielsen AB, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Ottosen CI, Sengeløv M, Skaarup KG, Pareek M, Müller-Wieland D, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.

2026-01-12

10.1001/jamainternmed.2025.7286

High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults

Niklas Dyrby Johansen, Daniel Modin, Matthew M. Loiacono, Rebecca C. Harris, Marine Dufournet et al. (38 authors)

New England Journal of Medicine2025-08-3019 citations

10.1056/nejmoa2509907

Interventions

DRUGCOVID-19

DRUGRNA-BASED VACCINE

DRUGEfluelda

DRUGinjektionsvæske

DRUGsuspension i fyldt injektionssprøjte

DRUGVaxigriptetra

DRUGInfluvactetra

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Hospitalization due to influenza or pneumonia [composite endpoint]	—

Secondary

Measure	Time frame
1) Hospitalization for any cardio-respiratory disease [composite endpoint], 2) All-cause hospitalization, 3) All-cause mortality, 4) Hospitalization for influenza, 5) Hospitalization for pneumonia	—

Countries

Denmark

Outcome results

None listed